Contact Us

Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Infertility means not being able to become pregnant after a year of trying. Drugs, Assisted Reproductive Technology (ART), surgery, artificial insemination,   and in vitro fertilization are common treatments.  

Statistics:

The global infertility drugs and devices market is estimated to account for US$ 9,702.4 Mn in terms of value by the end of 2027.

Global Infertility Drugs and Devices Market: Drivers

Increasing prevalence of infertility is expected to propel growth of the global infertility drugs and devices market over the forecast period. For instance, according to the National Survey of Family Growth data published in September 2018, 15.5% of all women who intend to become pregnant are infertile and 6.7% of married women aged 15 to 44 years are infertile, in the U.S.

Moreover, increasing homosexual population is also expected to aid in growth of the market. For instance, in March 2019, Williams Institute at the UCLA School of Law reported that around 4.5% of the U.S. adults were identified as lesbian, gay, bisexual or transgender.

Statistics:

North America held dominant position in the global infertility drugs and devices market in 2019, accounting for 35.7% share in terms of value, followed by Europe and Asia Pacific, respectively.

Figure 1: Global Infertility Drugs and Devices Market Share (%) Value, By Region, 2019

Infertility Drugs and Devices  | Coherent Market Insights

Global Infertility Drugs and Devices Market: Restraints

Limited insurance coverage for ART is expected to hinder growth of the market. ART is a relatively new and yet to be fully proven process in many countries. Such a status causes insurance companies to be apprehensive about covering expenses. For instance, in Canada, there is limited fund for IVF and intracytoplasmic sperm injection and hence infertile couples have to bear the cost of treatment. The average cost for infertility treatment in Canada is quite expensive and ranges from between US$ 10,000 to US$ 20,000.

Moreover, high prevalence of sexually transmitted diseases with erectile dysfunction drug users is also expected to hinder growth of the market. PDE 5 inhibitors, though the first line treatment in erectile dysfunction, are associated with a major concern of the transfer of sexually transmitted diseases (STDs). Various studies carried out to analyze differences in the prevalence of STDs among men who use erectile dysfunction drugs versus those who do not have reported that users of erectile dysfunction drugs had higher rates of STDs, particularly HIV and Chlamydia infection, than the non-users.

request-sample

Infertility Drugs and Devices Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 6,096.7 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 5.8% 2027 Value Projection: US$ 9,702.4 Mn
Geographies covered:
  • North America: U.S., Canada
  • Latin America: Brazil, Argentina, Mexico, Rest of Latin America
  • Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
  • Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, Rest of Middle East
  • Africa: North Africa, Central Africa, South Africa
Segments covered:
  • By Type:
    • Infertility Drugs: Clomiphene citrate, Sex hormones, Gonadotropins, Bromocriptine, Cabergoline, Imipramine, Letrozole, Metformin.
    • Infertility Devices: Equipment, Accessories.
  • By Gender: Male, Female.
Companies covered:

Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., Pfizer, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc., Mylan Pharmaceuticals Inc., Ferring Pharmaceuticals, Cipla Ltd, Aspargo Laboratories, Inc., Aurobindo Pharma Ltd., Lupin Limited, Novartis International AG, Daré Bioscience, Inc., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals, and Dr. Reddys Laboratories Ltd

Growth Drivers:
  • Increasing prevalence infertility
  • Approval and launch of new products
Restraints & Challenges:
  • Product recall

Global Infertility Drugs and Devices Market: Opportunities 

Increasing rate of literacy is expected to offer lucrative growth opportunities for players in the global infertility drugs and devices market. For instance, according to United Nations Children's Fund, globally, the youth literacy rate increased from 83% to 91% during 1985-2018.

Moreover, expiry of drug patents is expected to offer lucrative opportunities for development of generics. For instance, Eli Lilly and Company’s drug, Cialis used for treatment of erectile dysfunction, lost patent protection in September 2018. In October 2018, Teva Pharmaceutical launched a generic version of Cialis in the U.S.

Statistics:

The global infertility drugs and devices market was valued at US$ 6,096.7 Mn in 2019 and is forecast to reach a value of US$ 9,702.4 Mn by 2027 at a CAGR of 5.8% between 2020 and 2027.

Figure 2: Global Infertility Drugs and Devices Market Value (US$ Mn), 2016 – 2027

Infertility Drugs and Devices  | Coherent Market Insights

Market Trends/Key Takeaways

Initiatives to increase awareness regarding human reproductive technologies is expected to propel growth of the market. For instance, in February 2020, Cryos USA, a sperm and egg bank based in the U.S., held a scientific symposium on Assisted Reproductive Technology (ART).

The market is witnessing increasing launch of generics. For instance, in March 2019, Dr. Reddy's Laboratories launched a generic version of Cialis (Tadalafil) tablets for treatment of erectile dysfunction, in the U.S. market.

Global Infertility Drugs and Devices Market: Competitive Landscape

Major players operating in the global infertility drugs and devices market include, Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., Pfizer, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc. Mylan Pharmaceuticals Inc., Ferring Pharmaceuticals, Cipla Ltd, Aspargo Laboratories, Inc., Aurobindo Pharma Ltd., Lupin Limited, Novartis International AG, Daré Bioscience, Inc., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals, and Dr. Reddys Laboratories Ltd.

Global Infertility Drugs and Devices Market: Key Developments

Major players in the market are also focused on adopting partnership strategies to expand their product portfolio. For instance, in May 2020, Daré Bioscience, Inc., a developer of women’s health solutions partnered with Health Decisions, Inc., a full-service contract research organization (CRO) specializing in women’s health clinical research and diagnostic development, under which Health Decisions will exclusively provide CRO services within the U.S. to support R&D of Daré’s pipeline of contraception, fertility, and gynecological disorders products.

Major players in the market are also focused on launching generic drugs to expand their product portfolio. For instance, in September 2019, Lupin Limited launched Sildenafil tablets, USP of 25 mg, 50 mg, and 100 mg, a generic version of Pfizer Inc.’s Viagra tablets.

Infertility Drugs and Devices used for treating infertility in male and female. Factors such as endometriosis, ovarian disorders, uterine disorders, tubal disorders, and hormonal disorders are the major cause of female infertility, whereas male infertility is caused by azoospermia, varicocele, ejaculation disorders, and erectile dysfunction. Treatment procedure constitutes of drugs, Assisted Reproductive Technology (ART), surgery, artificial insemination, and in vitro fertilization. Increasing prevalence of erectile dysfunction, increasing research and development, new product approval, and adoption of expansion strategies from major players operating in the market is expected to propel the market growth during the forecast period.

Key features of the study:

  • This report provides in-depth analysis of the Global Infertility Drugs and Devices market  and provides market size (US$ million) and compound annual growth rate (CAGR %) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategy adopted by key players
  • It profiles key players in the Global Infertility Drugs and Devices market  based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include, Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., Pfizer, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc., Mylan Pharmaceuticals Inc., Ferring Pharmaceuticals, Cipla Ltd, Aspargo Laboratories, Inc., Aurobindo Pharma Ltd., Lupin Limited, Novartis International AG, Daré Bioscience, Inc., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals, and Dr. Reddys Laboratories Ltd
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
  • The Global Infertility Drugs and Devices market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Global Infertility Drugs and Devices market

Detailed Segmentation:

  • Global Infertility Drugs and Devices Market, By Type:
    • Infertility Drugs
      • Clomiphene citrate
      • Sex hormones
      • Gonadotropins
      • Bromocriptine
      • Cabergoline
      • Imipramine
      • Letrozole
      • Metformin
    • Infertility Devices
      • Equipment 
      • Accessories
  • Global Infertility Drugs and Devices Market, By Gender:
    • Male
    • Female
  • Global Infertility Drugs and Devices Market, By Region:
    • North America
      • By Type:
        • Infertility Drugs
          • Clomiphene citrate
          • Sex hormones
          • Gonadotropins
          • Bromocriptine
          • Cabergoline
          • Imipramine
          • Letrozole
          • Metformin
        • Infertility Devices
          • Equipment 
          • Accessories
      • By Gender
        • Male
        • Female
      • By Country
        • U.S.
        • Canada
    • Latin America
      • By Type:
        • Infertility Drugs
          • Clomiphene citrate
          • Sex hormones
          • Gonadotropins
          • Bromocriptine
          • Cabergoline
          • Imipramine
          • Letrozole
          • Metformin
        • Infertility Devices
          • Equipment 
          • Accessories
      • By Gender
        • Male
        • Female
      • By Country
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Type:
        • Infertility Drugs
          • Clomiphene citrate
          • Sex hormones
          • Gonadotropins
          • Bromocriptine
          • Cabergoline
          • Imipramine
          • Letrozole
          • Metformin
        • Infertility Devices
          • Equipment 
          • Accessories
      • By Gender
        • Male
        • Female
      • By Country
        • U.K.
        • Germany
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Type:
        • Infertility Drugs
          • Clomiphene citrate
          • Sex hormones
          • Gonadotropins
          • Bromocriptine
          • Cabergoline
          • Imipramine
          • Letrozole
          • Metformin
        • Infertility Devices
          • Equipment 
          • Accessories
      • By Gender
        • Male
        • Female
      • By Country
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Type:
        • Infertility Drugs
          • Clomiphene citrate
          • Sex hormones
          • Gonadotropins
          • Bromocriptine
          • Cabergoline
          • Imipramine
          • Letrozole
          • Metformin
        • Infertility Devices
          • Equipment 
          • Accessories
      • By Gender
        • Male
        • Female
      • By Country
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • By Type:
        • Infertility Drugs
          • Clomiphene citrate
          • Sex hormones
          • Gonadotropins
          • Bromocriptine
          • Cabergoline
          • Imipramine
          • Letrozole
          • Metformin
        • Infertility Devices
          • Equipment 
          • Accessories
      • By Gender
        • Male
        • Female
      • By Country
        • North Africa
        • Central Africa
        • South Africa
  • Company Profiles
    • Apricus Biosciences, Inc. *
      • Company Overview
      • Product Portfolio
      • Key Highlights
      • Financial Overview
      • Strategies
    • Bayer AG
    • Cristalia Produtos Quimicos Farmaceuticos Ltda.
    • Dong-A Pharmaceutical Co. Ltd.
    • Eli Lilly and Company
    • Meda Pharmaceuticals, Inc.
    • Pfizer, Inc.
    • S.K. Chemicals Co. Ltd.
    • Vivus, Inc.
    • Mylan Pharmaceuticals Inc.
    • Ferring Pharmaceuticals
    • Cipla Ltd
    • Aspargo Laboratories, Inc.
    • Aurobindo Pharma Ltd.
    • Lupin Limited
    • Novartis International AG
    • Daré Bioscience, Inc.
    • Torrent Pharmaceuticals Ltd.
    • Alembic Pharmaceuticals
    • Dr. Reddys Laboratories Ltd
  •  “*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Type
      • Market Snippet, By Gender
      • Market Snippet, By Country
      • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Highlights
    • Product launch
    • PEST Analysis
    • Technological Advancements
    • Regulatory Scenario
    • Mergers and Acquisitions
    • Impact of COVID19 on market
  4. Global Infertility Drugs and Devices Market, By Type, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Infertility Drugs
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Clomiphene citrate
        • Sex hormones
        • Gonadotropins
        • Bromocriptine
        • Cabergoline
        • Imipramine
        • Letrozole
        • Metformin
    • Infertility Devices
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
        • Equipment 
        • Accessories
  5. Global Infertility Drugs and Devices Market, By Gender, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Male
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Female
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Infertility Drugs and Devices Market, By Region, 2019 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2026
    • North America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Gender, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Gender, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Gender, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Spain
        • Italy
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Gender, 2016 – 2027, (US$ Mn))
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • Japan
        • India
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Gender, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC Countries
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Gender, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • North Africa
        • Central Africa
        • South Africa
  7. Competitive Landscape
    • Company Profiles
      • Apricus Biosciences, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bayer AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cristalia Produtos Quimicos Farmaceuticos Ltda.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Dong-A Pharmaceutical Co. Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eli Lilly and Company
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Meda Pharmaceuticals, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Pfizer, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • S.K. Chemicals Co. Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Vivus, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Mylan Pharmaceuticals Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ferring Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Cipla Ltd
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Aspargo Laboratories, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Aurobindo Pharma Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Lupin Limited
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Novartis International AG
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Daré Bioscience, Inc.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Torrent Pharmaceuticals Ltd.
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Alembic Pharmaceuticals
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Dr. Reddys Laboratories Ltd
        • Company Overview
        • Product Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 22 market data tables and 14 figures on “Infertility Drugs and Devices Market - Global forecast to 2027”.

Frequently Asked Questions

The Global Infertility Drugs and Devices market size was valued at US$ 6,096.7 million in 2019 and is estimated to exhibit a CAGR of 5.8% between 2020 and 2027.
Infertility Drugs and Devices segment held the major market share in 2019 owing increasing prevalence of infertility is expected to propel growth of the global Infertility Drugs and Devices market over the forecast period.
Major factor driving the growth of Global Infertility Drugs and Devices market during the forecast period increasing prevalence infertility, new product launch, and adoption of expansion strategies from major companies.
Major factors hampering the growth of the Global Infertility Drugs and Devices market during the forecast period constitutes of limited insurance coverage.
North America market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are Apricus Biosciences, Inc., Bayer AG, Cristalia Produtos Quimicos Farmaceuticos Ltda., Dong-A Pharmaceutical Co. Ltd., Eli Lilly and Company, Meda Pharmaceuticals, Inc., Pfizer, Inc., S.K. Chemicals Co. Ltd., Vivus, Inc. Mylan Pharmaceuticals Inc., Ferring Pharmaceuticals, Cipla Ltd, Aspargo Laboratories, Inc., Aurobindo Pharma Ltd., Lupin Limited, Novartis International AG, Daré Bioscience, Inc., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals, and Dr. Reddys Laboratories Ltd
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner